Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)

This study has been completed.
Sponsor:
Collaborators:
Merck A.E., Greece
Merck OY, Finland
Merck B.V., Netherlands
Merck A.B., Sweden
Merck, S.A., Portugal
Information provided by (Responsible Party):
Merck KGaA
ClinicalTrials.gov Identifier:
NCT01080027
First received: March 2, 2010
Last updated: July 30, 2014
Last verified: July 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2011
  Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)